This article was originally published in The Gray Sheet
Executive SummaryNew CEO effective May 7 is Frank Fischer, who served as president and CEO of Ventritex between 1987 and 1997. Fischer replaces company co-founder Wesley Sterman, MD, who remains chairman of the board. In announcing Fischer's appointment, the company reports that it is streamlining operations by reducing its U.S. work force by about one-third, scaling back manufacturing capacity and cutting general and administrative expenses "in several areas." The company, which manufactures the Port-Access minimally invasive system for stopped-heart coronary artery bypass grafting procedures, will book a charge related to the restructuring. Heartport says it is expanding its sales force "by moving more clinical training specialists into the field to work directly with surgical teams at their hospitals"
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.